Contract

Supply Planner

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Dublin, Ireland

In Person

Category
Operations & Logistics (1)
Required Skills
Inventory Management
SAP Products
Excel/Numbers/Sheets

Get referred to Viatris

See people who can refer or advise you

Requirements
  • Proven relevant supply chain/manufacturing experience.
  • Qualification in a Business-Related discipline or Supply Chain.
  • Previous Rapid Response and/ or SAP experience a distinct advantage
  • Good knowledge of Microsoft Office systems essential especially Microsoft Excel.
  • Strong planning and analytical skills, attention to detail and excellent communication skills; experience with planning process development and rollout; ability to be a change leader in Viatris.
Responsibilities
  • Maintain and update master data and planning parameters in Rapid Response and SAP for Rapid Response to produce best supply plan.
  • Monitor and maintain reason codes for out of stocks and maintain commentary on actions plans to resolve the out of stock per SKU.
  • Firm market requirements based on planning parameters (demand, safety stock, MOQ, etc) to minimize out of stocks.
  • Ensure firmed supply plans/ purchase orders are executed on time by supplier.
  • Develop and execute supply plans when there are upstream constraints in the supply chain (Materials, site capacities) along with internal guidelines to give each market the best supply plan.
  • Manage bulk inventory in both internal and external packaging sites, making sure there is no bulk obsolescence, market requirements are met, and packaging sites meet all commitments.
  • Agreeing and monitoring of suppliers’ delivery dates and escalate where issues arise.
  • Manage market inventory in line with inventory strategies as agreed with senior supply chain leads.
  • Determine mode of transport for shipments in line with business strategy, minimise amount transported by air and to track and monitor reason for air.
  • Monitor market demand changes within managed molecules month on month, recognizing the drivers for changes and if required, to be in position to explain changes to different stakeholders.
  • Support and deliver company/department goals and objectives as required.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Access-driven medicines support recurring demand in emerging and developed markets.[5]
  • Complex generics and biosimilars improve mix versus plain commodity generics.[5]
  • The July 2026 yen term loan adds liquidity and refinancing flexibility.[1]

What critics are saying

  • Generic pricing pressure from Teva and Sandoz compresses margins quickly.[5]
  • Debt refinancing and covenant compliance constrain capital allocation and dividend capacity.[1]
  • Biosimilar competition from Biocon Biologics threatens Semglee-related growth.[5]

What makes Viatris unique

  • Viatris combines Mylan and Upjohn, bridging generics and branded medicines.[1]
  • It sells medicines across more than 165 countries and territories.[11]
  • Its portfolio spans branded, generic, complex generic, and biosimilar products.[7]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.